In a moment that reveals how deeply political the science of immunity has become, Moderna's mRNA-based influenza vaccine has received federal approval in the United States after an unusual regulatory reversal — the FDA having initially refused even to review the application earlier this year. The vaccine, mFlusiva, is now cleared for adults 50 and older, arriving at a time when Moderna urgently needs new commercial footing as its pandemic-era revenue fades. The episode is less a simple story of scientific progress than a window into the fractured relationship between public health institutions
Moderna's mRNA flu vaccine wins FDA approval after regulatory reversal
The unusual public spat underscored how polarized mRNA vaccines have become
Mark
Why did the FDA initially reject the application if an advisory panel would later vote unanimously to approve it?
Mimi
That's the question everyone's asking. The rejection in February was so abrupt and so quickly reversed that it suggests either internal disagreement at the agency or external pressure—or both. The timing and the reversal make it look less like a scientific decision and more like a political one.
Mark
Is mFlusiva actually a better flu vaccine than what's already available?
Mimi
The source material doesn't tell us that. We know it's based on mRNA technology, which is novel for flu, but there's no head-to-head comparison data mentioned. The accelerated approval for older adults actually comes with a requirement to prove its benefit in that group after it's on the market.
Mark
Why does the combination Covid-flu vaccine matter so much to Moderna?
Mimi
Because it's a single shot instead of two. That's convenience for patients and potentially higher uptake. Europe approved it, which proves the concept works. But the FDA's hesitation on the combo product—asking for more data on the flu component alone—created this whole bottleneck.
Mark
Is Moderna in trouble financially without Covid vaccine revenue?
Mimi
That's the real story underneath this one. The company built itself on pandemic demand that's now evaporating. This flu vaccine is supposed to be the bridge to a sustainable business. If it doesn't work or doesn't sell, they have a serious problem.
Mark
What does the post-marketing trial requirement mean for patients?
Mimi
It means older people who get this vaccine are essentially part of an ongoing study. The company has to prove it actually prevents flu in that age group. It's not unusual for accelerated approvals, but it does mean the evidence isn't complete yet.
O Pulso
- Moderna's path to approval was anything but routine — the FDA's rare public refusal to even review the application in February sent shockwaves through the pharmaceutical world before the agency reversed course almost immediately.
- The whiplash exposed something deeper: mRNA technology, once celebrated as a triumph of modern medicine, has become a flashpoint in America's culture wars, entangling regulatory decisions in political currents far beyond the laboratory.
- An advisory panel's unanimous recommendation in June helped stabilize the process, but the damage to institutional credibility lingered, raising questions about what forces — internal or external — had shaped the FDA's initial stance.
- Moderna's ambition to sell a single combination Covid-flu shot in the US remains stalled; the company withdrew that application in May 2025 and is still waiting to learn whether it can resubmit, while Europe has already approved the combo product.
- mFlusiva is now heading to select retail shelves within weeks, but older adults 65 and up remain under an accelerated approval condition — meaning the vaccine must still prove itself in post-market trials even as real people begin receiving it.
In a moment that reveals how deeply political the science of immunity has become, Moderna's mRNA-based influenza vaccine has received federal approval in the United States after an unusual regulatory reversal — the FDA having initially refused even to review the application earlier this year. The vaccine, mFlusiva, is now cleared for adults 50 and older, arriving at a time when Moderna urgently needs new commercial footing as its pandemic-era revenue fades. The episode is less a simple story of scientific progress than a window into the fractured relationship between public health institutions, political pressure, and the technologies that emerged from Covid-19.
Moderna has won federal approval for mFlusiva, an influenza vaccine built on messenger RNA technology, cleared for adults 50 and older. The authorization comes after a turbulent regulatory journey that began in February, when the FDA took the rare step of refusing to even review the application — a public rebuke that stunned the industry before the agency reversed itself almost immediately. An advisory panel voted unanimously in June to recommend approval, and the final authorization followed this week. Doses are expected in select retail locations within weeks.
The approval matters enormously to Moderna's financial future. The company's Covid-19 vaccine business has contracted sharply as pandemic demand faded, and diversifying its pipeline has become urgent. The flu vaccine sits at the center of that strategy, though the road to market proved far more fraught than anticipated.
The regulatory turbulence also reflects a larger fracture in how mRNA technology is perceived in the United States. What began as a scientific question has become entangled with political divisions over vaccination and public health authority. The FDA's initial rejection — followed by its swift reversal — suggested internal disagreement, external pressure, or both, and the episode left the agency's credibility visibly strained.
A separate ambition remains unresolved: Moderna had sought approval for a single shot protecting against both Covid-19 and influenza, a product it successfully brought to European regulators in February. But after the FDA requested additional data before considering the combination product, Moderna withdrew that US application in May 2025 and is still awaiting guidance on whether it can resubmit.
For now, mFlusiva enters the market under conditions. The accelerated approval for adults 65 and older requires Moderna to conduct post-marketing trials confirming the vaccine actually prevents influenza in that population — meaning data collection continues even as distribution begins. The company must simultaneously manage manufacturing, supply, and the expectations of the oldest and most vulnerable Americans it is trying to protect.
Moderna has secured federal approval for an influenza vaccine built on messenger RNA technology, marking a significant regulatory reversal for the company after the Food and Drug Administration initially blocked the application just months earlier. The vaccine, called mFlusiva, is cleared for adults aged 50 and older—with standard approval for those between 50 and 64, and accelerated approval for those 65 and up. The company expects to have doses available in select retail locations within weeks.
The approval represents a crucial pivot for Moderna as it searches for new revenue streams beyond the Covid-19 vaccines that transformed it into a household name during the pandemic. That business has contracted sharply as demand has cooled, leaving the company dependent on diversifying its pipeline. The flu vaccine is central to that strategy, but the path to approval proved unexpectedly turbulent.
In February, the FDA stunned the company by refusing to even review Moderna's application—a rare and public rejection that caught many observers off guard. The agency reversed course almost immediately afterward, but the episode exposed deep tensions around mRNA vaccines in the American regulatory and political landscape. An FDA advisory panel voted unanimously to recommend approval in June, clearing the way for the final authorization this week.
The regulatory drama also reflects a broader dispute over vaccine combination strategies. Moderna had pursued a single shot that would protect against both Covid-19 and influenza, which the company successfully brought to European regulators in February. But when the FDA requested additional data on the standalone flu vaccine before considering the combination product, Moderna withdrew that application from the United States in May 2025. The company is still waiting for guidance from the agency on whether it can resubmit the combo vaccine, a decision that remains pending.
The unusual public conflict between a major pharmaceutical company and its primary regulator underscores how polarized the conversation around mRNA technology has become in the United States. What was once a scientific and medical question has become entangled with broader political divisions over vaccination policy and public health authority. The FDA's initial rejection, followed by its quick reversal, suggested internal disagreement or external pressure—or both—within the agency itself.
Moderna will be required to conduct a post-marketing clinical trial to confirm that mFlusiva actually prevents influenza in people 65 and older, a condition attached to the accelerated approval pathway. This means real-world data collection will continue even as the vaccine enters the market, a common requirement for drugs and vaccines approved on an expedited schedule. The company now faces the practical challenge of manufacturing and distributing the vaccine while managing expectations around its effectiveness in the oldest and most vulnerable population.
Citações Notáveis
Moderna expected supply to be available in select retailers in the coming weeks— Moderna statement
Quer a matéria completa?
Leia o original em The Edge Malaysia ↗
Health & Medicine